Not for release, publication ordistribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan or any other jurisdiction in which such release, publication or distribution would be unlawful. Please note the important information at the end of this announcement.

‍

Ad-hoc: Record quarter for Cantourage-Group: EUR 25.6 million revenue in Q1 2025 - for the first time EUR 10.7 million revenue in one month

Berlin, April 10, 2025 -Cantourage Group SE (hereinafter “Cantourage”, ISIN: DE000A3DSV01,www.cantourage.com), Europe's leading listed medical cannabis company, has completed the strongest quarter in its history: In the first quarter of 2025, the company generated revenues EUR 25.6 million - a new record.

In March 2025, the Berlin-based company also generated double-digit monthly sales for the first time: at over EUR 10.7 million, the previous record from December 2024 (EUR 8.5 million) was significantly exceeded.

Demand for Cantourage cannabis flowers continues to grow significantly

The continued strong increase indemand for Cantourage cannabis flowers is clearly reflected in the company's sales performance: In 2024 as a whole, the company generated sales revenues of EUR 51.4 million, which corresponds to an increase of 118 percent compared tothe previous year (2023: EUR 23.6 million).

‍

About Cantourage

Cantourage is the leading European company for the production and distribution of medical cannabis. Cantourage enables growers worldwide to sell products in European medicalmarkets. Founded in 2019, the company works with more than 60 cannabis growers from 18 countries. Cantourage ensures the highest pharmaceutical quality standards along the value chain and offers products in all relevant market segments: dried flowers, extracts, dronabinol and cannabidiol. The company has been listed on the Frankfurt Stock Exchange since November 11, 2022 and is listed under the ticker symbol “HIGH”.

Press contacts:
Pia Senkel | pia.senkel@tonka-pr.com | +49 (0) 173 3702649
Klaas Geller | klaas.geller@tonka-communications.de | +49 (0) 176 74717519

‍

Important information: This announcement contains information for the purposes of Article 17 of Regulation (EU) No 596/2014 (Market Abuse Regulation). This announcement does not constitute an offer to the public or an advertisement for a public offer to sell securities, in particular not within the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).This ad hoc announcement was published via the electronic informationdistributor EQS News.